Answers are grounded in this paper and cite their sources.
Post hoc analysis evaluates efficacy and safety of therapies in ulcerative colitis, showing similar outcomes across age groups, indicating treatment equity.
Background Older adults with ulcerative colitis (UC) are often undertreated with advanced therapies due to safety concerns. We evaluated whether outcomes differ by age in randomized trials. Methods Post hoc analysis of 2841 participants from 13 UC induction trials of biologics and JAK inhibitors compared efficacy (patient-reported outcomes 2 response/remission, clinical remission, endoscopic improvement) and safety between patients ≥60 years of age vs <60 years of age. Results Efficacy and safety outcomes were similar across age groups, with minor therapy-specific variation. Hospitalization was numerically higher in older adults. Conclusions Advanced therapies show comparable efficacy and safety in UC regardless of age.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: